INTRODUCTION
For more than 10 years, data collection of therapeutic apheresis procedures has been one of the goals of the Apheresis Study Group of the Italian Society of Nephrology, a small task force, which published the ''Guidelines for Therapeutic Apheresis in Nephrology'' in 1999 [1] , and primarily considered the establishment of a Registry as a safety and quality issue.
Therapeutic apheresis has been indicated in several diseases in many different clinical fields, from neurology to dermatology, from organ transplantation to metabolic errors, from hematology to nephrology. Data collection of the single procedures is cumbersome, and requires nowadays a large database with a well-organized staff: it is therefore still limited, and largely based on personal interest and initiative. Moreover, most of the time, productive apheresis largely overcomes therapeutic apheresis, and little is known about therapeutic procedures practised, especially including technical issues, local distribution, and/ or regional clusters in diseases, together with incidence and pattern of adverse events. The establishment of a Registry, where all the available data can be organized and analyzed, therefore, becomes a priority for all the professionals involved in apheresis [2] [3] [4] [5] .
Nephrologists have been very interested in therapeutic apheresis, partly due to their attitude towards extracorporeal blood treatments, and partly due to the fact that they faced kidney diseases for which there was a strong indication for plasma removal and substitution. Later, plasma treatment instead of plasma exchange was introduced and, again, intensive care specialists and nephrologists were equipped with filtration techniques, due to their experience with hemodialysis and hemofiltration, and cascade techniques with plasma fractionation were introduced. More recently, whole blood treatment, like hemoperfusion or hemoadsorption, has been developed on a larger clinical basis, and once again the procedure is much like hemodialysis, thus focusing the strong interest of the nephrological community.
The Apheresis Group of the Italian Society of Nephrology started to collect data on apheresis in 1994, mainly in Nephrological Units in Italy, but since the beginning, the Group has addressed its efforts in the collection and analysis of therapeutic apheresis procedures of all kinds, performed also in other Centers and for the treatment of non-nephrological diseases. Following the initial experience during 1994-1999, data collection was performed by a standardized questionnaire that was subsequently modified and improved on an electronic basis. The Registry is now Internet based; the website is www.aferesi.it and it is coordinated by Stefano Passalacqua, MD (passalacqua@aferesi.it).
The Registry is open, and the participation of other Scientific Societies is appreciated. A continuous collaboration throughout the years has been maintained with SIDE, the Italian Society for Apheresis, which has recently published data of a national survey of apheresis in Italy [6] Therapeutic apheresis procedures were performed by means of plasma exchange (PE) through centrifugation or filtration, plasma treatment (TP), which included different filtration, fractionation and adsorption devices, cell apheresis limited to photoapheresis (CA), and whole blood treatment on adsorbent columns (TS) for selective removals (i.e., LDL-cholesterol, bilirubin).
Vascular access for apheresis was obtained through artero-venous fistula in 13.4%, central venous catheters in 10.45%, and through a variable combination of peripheral veins in all other cases. Anticoagulation was performed with heparin in 82%, a combination of heparin and citrate in 9.7%, and with citrate only in 4.9%.
No side effects were reported in 97.08% of procedures. The reported side effects were mild in the vast majority of cases, mainly linked with hypotension, citrate toxicity, and blood access-related problems. There were 5 deaths recorded, corresponding to 0.03%; 4 patients were treated with PE and 1 with TP.
A total number of 1,477 patients were enrolled, 741 males and 736 females, each of whom received on average 10.5 procedures. The procedures were separated into groups of treatment, according to the kind of procedure and to timing: a group of treatment was performed with the same technique, was never longer than one year, and the time that elapsed between one procedure and the other did not exceed 35 days. A total of 2,132 groups of treatment was recorded, 593 of these in vasculitis and systemic diseases, 497 in neurologic, 330 in hematologic, and 249 in nephrologic diseases.
The five most frequent diseases treated by apheresis respectively were, as reported in Table I , Guillain Barre´syndrome in 167 cases, cryoglobulinemia in (Table II) .
PE accounted for 56.26% of the procedures, and, out of these, 50.44% were performed by filtration. TP was used in 40.18% of cases, namely with Protein A immunoadsorption (14.61%), LDL-cholesterol dextran sulfate adsorption (9.79%), and semiselective cascade filtration or double filtration (12.65%). CA, namely photopheresis for acute graft rejection, has been used in a small number of cases, and accounts for 0.85%, and TS (direct adsorption lipoprotein and molecular adsorption recirculating system) for 2.7% of procedures (Table III) The performances and results for the main diseases treated with apheresis are summarized in Table IV , where the lowest percentage of outcome for every category is in boldface.
DISCUSSION
The Registry was conceived within the Italian Society of Nephrology as a means to collect as many data as possible of the nephrologic activity in the small area of macromolecular plasma treatment [6] . It soon became evident that often Nephrologists, partly due to a personal interest or ability in extracorporeal treatments, partly due to local necessity, are called to treat non-nephrologic diseases. Moreover, other experts in Neurology, Immunology, Intensive Care, or Metabolic Diseases started therapeutic apheresis on their own, and later shared their experience with specialists in other fields. Initially, through the collaboration with the Italian Apheresis Society (SIDE), which mainly reported data from Apheresis Units and Blood Banks, and whose interdisciplinary character is well recognized, the idea of a common apheresis registry was undertaken, but it had to be postponed, due to the differences in the collection of data [7] .
An overview of the Registry is useful to point out that therapeutic apheresis procedures are largely distributed within nephrologic and non-nephrologic units all over Italy (nearly all the Italian regions are represented), although data are certainly underestimated, and that neurological diseases, namely Guillain Barre´syndrome and myasthenia gravis, are still within the top five treated diseases. Cryoglobulinemia and SLE, not necessarily accompanied by nephropathy, are the other most treated diseases together with TTP.
An interesting feature of the Registry, which is especially focused on therapy, is represented by the very large proportion of plasma treatment procedures, namely double filtration, plasma or whole blood adsorption and immunoadsorption, instead of plasma substitution by traditional plasma exchange, that indicates the preference for plasma treatment instead of plasma substitution. Great importance is, therefore, attributed to plasma treatment and to the minimization or avoidance of substitution fluids. In this respect, the pilot experience of immunoadsorption in neurologic diseases [8] and of plasma detoxification in liver failure is important to be recognized [9] , along with a protocol to assess the role of therapeutic apheresis in recurrent focal segmental glomerulosclerosis [10, 11] . Another field of interest is the treatment of severe hypercholesterolemia, which a 10-year survey reveals to be the current most treated disease. The Registry collects over 1,500 procedures, with a very small number of plasma exchanges, and a variety of selective procedures of LDL-apheresis that all proved to be safe and suitable for long-term treatment [12, 13] .
As regards blood access and the choice of anticoagulation, a nephrologic bias has to be considered, since over 13% of patients had an arterovenous fistula, and heparin was by far the most used anticoagulant, not only with plasma filtration, but also with other techniques, including plasma separation by centrifugation and plasma treatment by adsorption, where a mixture of citrate and heparin was generally employed. Therapeutic apheresis-related side effects are few, usually mild, although more common than in productive apheresis [7] . It has to be pointed out, however, that the loss of 5 patients, with a gross mortality of 0.03%, was reported in cases treated with PE in 4 cases, and with TP in 1 case, and this overview may confirm that plasma processing is generally safe and well tolerated by patients.
Notwithstanding being largely incomplete, the analysis of data collected in the Registry is sufficiently informative for at least two kinds of considerations: (1) the number of therapeutic apheresis procedures performed is certainly underestimated either in Blood Banks or in other Apheresis Centers, but it appears to be employed in many different clinical conditions in a quite homogeneous way all over the country, and (2) in our data, it appears that a definite trend to employ plasma treatments with different techniques, from cascade filtration to whole blood adsorption, can be recognized in order to achieve as often as possible the most selective plasma removal.
